These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434 [TBL] [Abstract][Full Text] [Related]
11. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A; Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606 [TBL] [Abstract][Full Text] [Related]
12. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023 [TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Shepherd J; Cooper K; Harris P; Picot J; Rose M Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404 [TBL] [Abstract][Full Text] [Related]
14. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396 [TBL] [Abstract][Full Text] [Related]
15. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Jansen JP; Buckley F; Dejonckheere F; Ogale S Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. Akiyama M; Kaneko Y; Kondo H; Takeuchi T Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256 [TBL] [Abstract][Full Text] [Related]
18. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. Tappeiner C; Miserocchi E; Bodaghi B; Kotaniemi K; Mackensen F; Gerloni V; Quartier P; Lutz T; Heiligenhaus A J Rheumatol; 2015 Apr; 42(4):706-11. PubMed ID: 25641892 [TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases. Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892 [TBL] [Abstract][Full Text] [Related]
20. [Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs]. Klein A Z Rheumatol; 2019 Sep; 78(7):599-609. PubMed ID: 31087133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]